rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

QuidelOrtho Corporation

QDEL · Nasdaq

Health CareDiagnostics & LabsSetting up

QDEL stood above a rising 150-day average in 2 of the last 52 weekly readings, and has been out of that trend for the last 37 weeks. It is 3.3% below that average now. Diagnostics & Labs: 52% of its 44 stocks in an uptrend (+5 points in four weeks); Health Care: 28% (−6 points in four weeks).

Statistics

Rotation
Setting up
Weeks in an uptrend
out for 37
Industry in uptrend
52% +5 in 4 wk
Insider buys, 12 months
$2.0M
Insider sales, 12 months
$112K
Officials’ trades on record
23
Institutions holding
227 (+10)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 2 of 52 weeks.

23 Apr – 22 Oct
18%36%53%Apr 26Jun 26Jul 26Sep 26Oct 26

Diagnostics & Labs: About half its stocks are in an uptrend and the share has been climbing. Health Care: A minority of its stocks are in an uptrend and the share has been slipping.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$281.1M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

23 disclosed lines: House 18, Senate 0, executive 5; 6 people.

WhoDidAmountTraded
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$1k–$15k31 Aug 2026filed 8 Oct 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$1k–$15k29 Jul 2026filed 22 Sep 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officebought$15k–$50k4 Jun 2026filed 22 Aug 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officesold$15k–$50k30 Apr 2026filed 1 Jul 2026
Donald J. Trump Executive branch: Office of Government EthicsWhite House Officebought$15k–$50k4 Mar 2026filed 14 May 2026
Byron Donalds House: U.S. House ClerkFL19sold$1k–$15k19 Oct 2023filed 8 Nov 2024
Byron Donalds House: U.S. House ClerkFL19soldspouse$1k–$15k19 Oct 2023filed 8 Nov 2024
Daniel S. Goldman House: U.S. House ClerkNY10sold$1k–$15k12 Jul 2023filed 13 Aug 2023
Byron Donalds House: U.S. House ClerkFL19bought$1k–$15k7 Dec 2022filed 8 Nov 2024
Byron Donalds House: U.S. House ClerkFL19boughtspouse$1k–$15k7 Dec 2022filed 8 Nov 2024
Tom Malinowski House: U.S. House ClerkNJ07bought$15k–$50k11 May 2021filed 23 Jun 2021
Tom Malinowski House: U.S. House ClerkNJ07sold$1k–$15k27 Apr 2021filed 12 Jun 2021

Insiders

Buy orders, 12 months9
Sale orders, 12 months1
Buyers · sellers6 · 1
WhoDidSharesTraded
Matthew StrobeckDirectorbought10,000at $23.9613 Feb 2026filed 13 Feb 2026
Joseph M. BuskyChief Financial Officerbought3,370at $23.6613 Feb 2026filed 13 Feb 2026
Joseph M. BuskyChief Financial Officerbought3,370at $23.6613 Feb 2026filed 19 Feb 2026
Brian J. BlaserPresident and CEObought10,540at $23.5913 Feb 2026filed 13 Feb 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders227+10 on the quarter
New · exited57 · 46
Reported value$1.4B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.added · filed 7 Aug 202611,202,523$196.2M+753,396+7.2%
FMR LLCadded · filed 13 Aug 20267,363,696$129.0M+772,544+11.7%
Newtyn Management, LLCadded · filed 14 Aug 20266,625,000$116.0M+2,066,528+45.3%
VANGUARD PORTFOLIO MANAGEMENT LLCadded · filed 13 Aug 20264,135,464$72.4M+103,696+2.6%
NEUBERGER BERMAN GROUP LLCadded · filed 13 Aug 20263,534,619$62.1M+2,004,205+131.0%
Invesco Ltd.added · filed 14 Aug 20263,473,432$60.8M+355,963+11.4%
AMERICAN CENTURY COMPANIES INCadded · filed 12 Aug 20263,307,079$57.9M+450,947+15.8%
Rubric Capital Management LPunchanged · filed 14 Aug 20263,306,281$57.9M00.0%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20263,070,054$53.8M+17,344+0.6%
STATE STREET CORPadded · filed 7 Aug 20262,978,639$52.2M+192,018+6.9%
31 Mar 2023 – 30 Jun 2026
219243266Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Jonathan Philip Siegrist Company insiderEVP of R&D & CTO · last 15 Oct 20260 · 0
Ronald Lee Bowman Company insiderChief Human Resources Officer · last 15 Sep 20260 · 0
Donald J. Trump Executive branchWhite House Office · last 31 Aug 20262 · 3
Bryan Michael Hanson Company insiderEVP Global Port. Mgmt & Mkting · last 15 Aug 20260 · 0
Micah W. Young Company insiderChief Financial Officer · last 15 Jul 20260 · 0
Ann D. Rhoads Company insiderDirector · last 25 Jun 20261 · 0
Edward L. Michael Company insiderDirector · last 25 Jun 20260 · 0
Evelyn S. Dilsaver Company insiderDirector · last 25 Jun 20260 · 0
John R. Chiminski Company insiderDirector · last 25 Jun 20260 · 0
Joseph D. Wilkins Jr. Company insiderDirector · last 25 Jun 20261 · 0
Kenneth F. Buechler Company insiderDirector · last 25 Jun 20260 · 1
Kenneth J. Widder Company insiderDirector · last 25 Jun 20260 · 1

Same industry

CDNA CareDxLeading+91%
NTRA NateraLeading+46%
XGN ExagenLeading+41%
PSNL PersonalisLeading+33%
BDSX BiodesixLeading+19%

Distance from each stock’s own 150-day average.

From its SEC filings

Operating profit marginFY 2025 · to 28 Dec 2025-33.7%
Free cash flow marginFY 2025 · to 28 Dec 2025-3.0%
Return on capital employedFY 2025 · to 28 Dec 2025-19.1%
Debt to equityFY 2025 · to 28 Dec 20251.50×
Research spendFY 2025 · to 28 Dec 20256.8%
Share count trendFY 2025 · to 11 Feb 20260.3%
Cash and equivalentsFY 2025 · to 28 Dec 2025$169.8M
Free cash flowFY 2025 · to 28 Dec 2025−$83.0M

Analyst forecasts

No analyst forecasts yet.